Introduction Selecting a qualified Nitrosamine Testing Laboratory in Canada requires verification of active Drug Establishment Licence (DEL) compliance, highly sensitive […]
Introduction Developing a Nitrosamine Testing Program from scratch for a multi-product generic drug portfolio requires a well-organized, cross-functional strategy that
Introduction Executing NDSRI Identification, Potency Prediction, and Confirmatory Quantification represents an important regulatory milestone for obtaining New Drug Application (NDA)
Introduction Acceptable Intake (AI) Limits for Nitrosamines Calculation is performed through linear low-dose extrapolation using rodent TD50 carcinogenicity bioassays or
Introduction NDSRI Quantification at Ultra-Low Levels requires advanced liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodologies capable of detecting mutagenic impurities at
Introduction Nitrosamine Testing for Antibiotics and Beta-Lactam APIs is a specialized analytical mandate focused on the detection, identification, and quantification
Introduction The critical operational and compliance difference between a nitrosamine screening method and a confirmatory method is primarily defined by
What Is the Difference Between a Nitrosamine Screening Method and a Confirmatory Method? Read More »
Introduction Nitrosamine Testing for Veterinary Drug Products is a critical analytical quality control process used to identify and quantify mutagenic
Introduction Nitrosamine Control Strategy Development Services offer a comprehensive, science-driven framework for identifying, quantifying, and controlling mutagenic N-nitroso impurities throughout
Introduction The primary technical consideration when comparing NDSRIs with simple nitrosamines lies in understanding how differences in molecular complexity and
